|
Jul 29
|
UniQure: Q2 Earnings Snapshot
|
|
Jul 29
|
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
|
|
Jul 22
|
uniQure to Announce Second Quarter 2025 Financial Results
|
|
Jun 2
|
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
|
|
May 29
|
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
|
|
Apr 21
|
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
|
|
Apr 21
|
FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
|
|
Apr 17
|
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
|
|
Feb 20
|
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%
|